Methods for the treatment of diseases or pathological states related to the degradation of the extracellular matrix, such as degenerative diseases atheriosclerosis, cancer, infection or other inflammatory diseases are disclosed, comprising administering compositions of lysine, proline, ascorbate, and their derivatives and synthetic analogues and vitamins, pro-vitamins and trace elements.

Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.

Neuren Pharmaceuticals Limited

Analogs of glycyl-prolyl-glutamate

Embodiments of this invention provide methods for thereapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and/or death of dopaminergic neurons and the adverse symptoms of such degeneration and/or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.

proline/atrophy

Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration

Analogs of glycyl-prolyl-glutamate

Cyclic G-2Allylproline in treatment of Parkinson's disease

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi